Quick investment opportunity based on recent news.
Entry Price should be around $2.00
Target Price should be around $2.50
Set a stop loss of 5% ($1.90)
Recent news about OncoCyte's drug Determarx shows signs to help battle lung cancer. Trials will start with patients this quarter and the company is presenting its findings at the North American Conference for Lung Cancer.